Abstract: Objective To systematically evaluate the relationship between metabolic syndrome and prostate cancer progression. Methods Multiple databases were searched by computer,and the time was limited from establishment to November 2021.Case-control studies or cohort studies on the association between metabolic syndrome and prostate cancer progression were collected and meta-analyses were performed according to the results of heterogeneity.Results A total of 10 case-control studies and 1 cohort study were included,13207 patients were included.Meta-analysis showed that Gleason score(≥8) in patients with metabolic syndrome after radical prostatectomy was higher than that in patients with non-metabolic syndrome(OR=1.83,95%CI:1.44~2.33),and pathological T stage(≥T3) was higher than that in patients with non-metabolic syndrome(OR=1.95,95%CI:1.28~2.96),the incidence of pelvic lymph node metastasis was higher than that of non-metabolic syndrome patients(OR=1.96,95%CI:1.47~2.61),and the incidence of positive surgical margin was higher than that of non-metabolic syndrome patients(OR=1.17,95%CI:1.04~1.33).Conclusion Compared with patients without metabolic syndrome,patients with metabolic syndrome have higher Gleason score,higher pathological T-stage,higher risk of pelvic lymph node metastasis,and higher incidence of positive surgical margins,suggesting a certain correlation between metabolic syndrome and the progression of prostate cancer.

Key words: metabolic syndrome, prostate cancer, Metaanalysis